Analyze Diet
Equine veterinary journal1985; 17(2); 83-96; doi: 10.1111/j.2042-3306.1985.tb02056.x

Clinical pharmacology and therapeutic uses of non-steroidal anti-inflammatory drugs in the horse.

Abstract: Weak organic acids possessing anti-inflammatory, analgesic and antipyretic properties--commonly known as aspirin-like drugs--have been used in equine medicine for almost 100 years. These non-steroidal anti-inflammatory drugs (NSAIDs) may be classified chemically into two groups; the enolic acids such as phenylbutazone and carboxylic acids like flunixin, meclofenamate and naproxen. All NSAIDs have similar and possibly identical modes of action accounting for both their therapeutic and their toxic effects. They block some part of the cyclo-oxygenase enzyme pathway and thereby suppress the synthesis of several chemical mediators of inflammation, collectively known as eicosanoids. The available evidence indicates that some of the newer NSAIDs have a reasonable safety margin but further studies are required. The toxicity of phenylbutazone in the horse has been investigated very thoroughly in recent years and it has been shown to cause renotoxicity and, most significantly, ulceration of the gastrointestinal tract when relatively high doses are administered. Several factors may predispose towards phenylbutazone toxicity in the horse, including breed and age, but high dosage is considered to be particularly important. The absorption into, and fate within, the body of NSAIDs are considered and particular attention is drawn to the ways in which these pharmacokinetic properties relate to the drugs' toxicity and clinical efficacy. In reviewing current knowledge of the clinical pharmacology of this important group of drugs, it is hoped to provide the clinician with a rational, scientific basis for their safe and effective use in equine practice.
Publication Date: 1985-03-01 PubMed ID: 3987667DOI: 10.1111/j.2042-3306.1985.tb02056.xGoogle Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research article discusses the therapeutic uses and effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), notably their application in equine medicine to treat inflammation, pain, and fever. The study covers the chemical classifications of NSAIDs, their mode of action, toxicity, and the factors contributing to toxicity, particularly addressing the pharmacokinetic properties related to the drug’s toxicity and efficacy.

Chemical Classification of NSAIDs

  • The study classifies NSAIDs into two chemical groups, enolic acids and carboxylic acids, with examples such as phenylbutazone for enolic acids and flunixin, meclofenamate, and naproxen for carboxylic acids.

Mode of Action of NSAIDs

  • NSAIDs function by blocking part of the cyclo-oxygenase enzyme pathway, thereby suppressing the synthesis of chemical mediators of inflammation termed eicosanoids.
  • This action accounts for both their therapeutic, which is treatment-oriented, and toxic effects.

Safety and Toxicity of NSAIDs

  • The research indicates that newer NSAIDs have a fair safety margin, but more studies are required to firmly establish this.
  • The study pays particular attention to the toxicity of phenylbutazone in horses, proven to cause kidney toxicity (renotoxicity) and ulceration of the gastrointestinal tract, particularly when administered in high doses.

Factors Contributing to NSAID Toxicity

  • The research suggests that factors like breed and age may predispose horses towards phenylbutazone toxicity. However, high dosage is outlined as the most significant contributor.

Pharmacokinetic Properties of NSAIDs

  • The study discusses the absorption of NSAIDs into the body, their fate within the body, and how these pharmacokinetic properties relate to the drugs’ toxicity and clinical efficiency. Pharmacokinetics mainly refers to what the body does to a drug, including absorption, distribution, metabolism, and excretion processes.

Conclusion

  • The article aims to provide practitioners with a scientific basis for the safe and effective use of NSAIDs in equine practice, by reviewing current knowledge of these drugs’ clinical pharmacology.

Cite This Article

APA
Lees P, Higgins AJ. (1985). Clinical pharmacology and therapeutic uses of non-steroidal anti-inflammatory drugs in the horse. Equine Vet J, 17(2), 83-96. https://doi.org/10.1111/j.2042-3306.1985.tb02056.x

Publication

ISSN: 0425-1644
NlmUniqueID: 0173320
Country: United States
Language: English
Volume: 17
Issue: 2
Pages: 83-96

Researcher Affiliations

Lees, P
    Higgins, A J

      MeSH Terms

      • Animals
      • Anti-Inflammatory Agents / adverse effects
      • Anti-Inflammatory Agents / blood
      • Anti-Inflammatory Agents / therapeutic use
      • Biotransformation
      • Drug Interactions
      • Horse Diseases / drug therapy
      • Horses
      • Kinetics
      • Metabolic Clearance Rate
      • Structure-Activity Relationship

      Citations

      This article has been cited 19 times.
      1. McLean AK, Falt T, Abdelfattah EM, Middlebrooks B, Gretler S, Spier S, Turoff D, Navas Gonzalez FJ, Knych HK. Transdermal Flunixin Meglumine as a Pain Relief in Donkeys: A Pharmacokinetics Pilot Study. Metabolites 2023 Jun 21;13(7).
        doi: 10.3390/metabo13070776pubmed: 37512483google scholar: lookup
      2. Mactaggart AG, Phillips CJC. Validating a Thoroughbred Racehorse Welfare Index through Horse Behaviour and Trainers' Reports of Welfare Issues in Their Horses. Animals (Basel) 2023 Jan 13;13(2).
        doi: 10.3390/ani13020282pubmed: 36670822google scholar: lookup
      3. Waller P, Lomnicka I, Lucas C, Johnson S, Dirikolu L. The medication violations in racehorses at Louisiana racetracks from 2016 to 2020. Vet Med Sci 2022 Mar;8(2):553-560.
        doi: 10.1002/vms3.724pubmed: 34989156google scholar: lookup
      4. Gugliandolo E, Crupi R, Biondi V, Licata P, Cuzzocrea S, Passantino A. Protective Effect of Silibinin on Lipopolysaccharide-Induced Inflammatory Responses in Equine Peripheral Blood Mononuclear Cells, an In Vitro Study. Animals (Basel) 2020 Nov 3;10(11).
        doi: 10.3390/ani10112022pubmed: 33153060google scholar: lookup
      5. Bauquier J, Tudor E, Bailey S. Effect of the p38 MAPK inhibitor doramapimod on the systemic inflammatory response to intravenous lipopolysaccharide in horses. J Vet Intern Med 2020 Sep;34(5):2109-2116.
        doi: 10.1111/jvim.15847pubmed: 32700419google scholar: lookup
      6. Tiwari M. The role of serratiopeptidase in the resolution of inflammation. Asian J Pharm Sci 2017 May;12(3):209-215.
        doi: 10.1016/j.ajps.2017.01.003pubmed: 32104332google scholar: lookup
      7. Borges RS, Palheta IC, Ota SSB, Morais RB, Barros VA, Ramos RS, Silva RC, Costa JDS, Silva CHTP, Campos JM, Santos CBR. Toward of Safer Phenylbutazone Derivatives by Exploration of Toxicity Mechanism. Molecules 2019 Jan 1;24(1).
        doi: 10.3390/molecules24010143pubmed: 30609687google scholar: lookup
      8. Worboys M, Toon E. Phenylbutazone (Bute, PBZ, EPZ): one drug across two species. Hist Philos Life Sci 2018 Mar 26;40(2):27.
        doi: 10.1007/s40656-018-0191-4pubmed: 29582183google scholar: lookup
      9. Guedes AGP, Aristizabal F, Sole A, Adedeji A, Brosnan R, Knych H, Yang J, Hwang SH, Morisseau C, Hammock BD. Pharmacokinetics and antinociceptive effects of the soluble epoxide hydrolase inhibitor t-TUCB in horses with experimentally induced radiocarpal synovitis. J Vet Pharmacol Ther 2018 Apr;41(2):230-238.
        doi: 10.1111/jvp.12463pubmed: 29067696google scholar: lookup
      10. Merey HA, Abd-Elmonem MS, Nazlawy HN, Zaazaa HE. Spectrophotometric Methods for Simultaneous Determination of Oxytetracycline HCl and Flunixin Meglumine in Their Veterinary Pharmaceutical Formulation. J Anal Methods Chem 2017;2017:2321572.
        doi: 10.1155/2017/2321572pubmed: 28811956google scholar: lookup
      11. Riesberg LA, Weed SA, McDonald TL, Eckerson JM, Drescher KM. Beyond muscles: The untapped potential of creatine. Int Immunopharmacol 2016 Aug;37:31-42.
        doi: 10.1016/j.intimp.2015.12.034pubmed: 26778152google scholar: lookup
      12. Vivancos M, Barker J, Engbers S, Fischer C, Frederick J, Friedt H, Rybicka JM, Stastny T, Banse H, Cribb AE. Pharmacokinetics and bioequivalence of 2 meloxicam oral dosage formulations in healthy adult horses. Can Vet J 2015 Jul;56(7):730-6.
        pubmed: 26130835
      13. Pairis-Garcia MD, Karriker LA, Johnson AK, Kukanich B, Wulf L, Sander S, Millman ST, Stalder KJ, Coetzee JF. Pharmacokinetics of flunixin meglumine in mature swine after intravenous, intramuscular and oral administration. BMC Vet Res 2013 Aug 13;9:165.
        doi: 10.1186/1746-6148-9-165pubmed: 23941181google scholar: lookup
      14. Kreuder AJ, Coetzee JF, Wulf LW, Schleining JA, KuKanich B, Layman LL, Plummer PJ. Bioavailability and pharmacokinetics of oral meloxicam in llamas. BMC Vet Res 2012 Jun 21;8:85.
        doi: 10.1186/1746-6148-8-85pubmed: 22720782google scholar: lookup
      15. Broome TA, Brown MP, Gronwall RR, Casey MF, Meritt KA. Pharmacokinetics and plasma concentrations of acetylsalicylic acid after intravenous, rectal, and intragastric administration to horses. Can J Vet Res 2003 Oct;67(4):297-302.
        pubmed: 14620867
      16. Ali BH. Comparative pharmacokinetics of salicylate in camels, sheep and goats. Eur J Drug Metab Pharmacokinet 2003 Apr-Jun;28(2):125-8.
        doi: 10.1007/BF03190500pubmed: 12877570google scholar: lookup
      17. Pyörälä S, Pätilä J, Sandholm M. Phenylbutazone and flunixin meglumine fail to show beneficial effects on bovine subclinical mastitis. Acta Vet Scand 1988;29(3-4):501-3.
        doi: 10.1186/BF03548648pubmed: 3256245google scholar: lookup
      18. Mbugua SW, Skoglund LA, Løkken P. Effects of phenylbutazone and indomethacin on the post-operative course following experimental orthopaedic surgery in dogs. Acta Vet Scand 1989;30(1):27-35.
        doi: 10.1186/BF03548065pubmed: 2782230google scholar: lookup
      19. Geor RJ, Petrie L, Papich MG, Rousseaux C. The protective effects of sucralfate and ranitidine in foals experimentally intoxicated with phenylbutazone. Can J Vet Res 1989 Apr;53(2):231-8.
        pubmed: 2713788